Humedics markets a system for bedside and instantaneous measurement of liver function. Patented device, consumables and a diagnostic drug allow an optimal market offering.
Humedics closes 6.3 million € financing round
Cash inflow enables for commercialization of the LiMAx test Berlin, Germany, November 10, 2014 – Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced the closing of a Series C financing round totaling more than 6.3 million Euro. Humedics’ business model, products and company development has attracted new international investors that will join the current private and public investors. The fin
Humedics successfully closed its first VC-financing round with Charité Biomedical Fund, VC Fonds Technologie, KfW, HTGF and Ventegis Capital AG
Humedics GmbH, a specialist for rapid and mobile measurement of the individual liver function at the bedside of the patient, today announced the closing of its first equity financing round. The Charité Biomedical Fund (CBF) managed by Peppermint VenturePartners led this round which included VC Fonds Technologie managed by IBB-Beteiligungsgesellschaft, the ERP Startfonds of the KfW, Ventegis and current investor High-Tech Gründerfonds. The funding enables Humedics to complete the final developm
High-Tech Gründerfonds invests in spin-off from Freie Universität Berlin and the Charité university hospital
Humedics markets an innovative method for instantaneous measurement of liver function at the patient’s bedside. Known as the LiMAx Test, which was developed at the Charité University Hospital in Berlin by Dr Martin Stockmann and refined into a measurement system together with Prof. Karsten Heyne of Freie Universität Berlin, is now able for the first time to precisely measure liver function. High-Tech Gründerfonds has invested about EUR 500,000 in the newly formed Humedics company for it t
28. Dec 2009